MTOR and prostate carcinoma: Activation of the PI3K-AKT-mTOR pathway is known to enhance cell survival in various cancers including prostate cancer,35 liver cancer36 breast cancer,37 and OS.38 Interestingly, our data showed that exposure to clemastine alone did not suppress AKT/mTOR signaling.